No chance for scientific innovation board! Lily medical withdrew its registration application and terminated its registration

Yiouda health on April 22. Last night, the website of Shanghai Stock Exchange disclosed the notice of termination of the stock issuance and registration procedure of the China Securities Regulatory Commission on the science and Innovation Board ([2022] No. 60), and Guangdong Lily Medical Technology Co., Ltd. (hereinafter referred to as "lily medical") withdrew its application documents for listing on the science and innovation board. According to Article 31 of the measures for the administration of the registration of initial public offering of shares on the science and Innovation Board (for Trial Implementation), the CSRC decided to terminate the registration procedures for the issuance of Baihe medical. Lily medical is a high-tech enterprise dedicated to the R & D and industrial application of innovative medical devices. Its main business is the R & D, production and sales of disposable medical devices in the fields of infusion management, blood purification and wound dressing. Its main products cover more than 80 categories, such as intravenous indwelling needle, central venous catheter, needle free infusion connector, hemodialysis catheter, hemoperfusion device and alginate dressing, It can be widely used in operating rooms, emergency departments, ICU Wards, Nephrology, vascular surgery, Hepatology and other departments to meet the clinical application needs of medical institutions at all levels. It is understood that Lily medical will be approved on March 4, 2021, and then submitted the registration application on April 8 of that year. Now after more than one year, the company finally missed the A-share.